Humacyte is trading 5.17% down at $0.63 after its August 12, 2026, second-quarter earnings release showed revenue and EPS misses.
- Revenue was $410,000 versus the $1.11 million consensus estimate; EPS was -$0.16 versus -$0.09 expected.
- The company highlighted strong Phase 3 dialysis results and plans for a supplemental BLA filing during the second half of 2026.
- Investors appear focused on weak near-term commercialization and the earnings shortfall.